Journal Article

INTRK/I Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients

Rittmeyer, Achim, Hugo, Tabea, Overbeck, Tobias Raphael, Schnalke, Juliane, Lukat, Laura, Reiffert, Annika, Schildhaus, Hans-Ulrich, Hinterthaner, Marc, Schmitz, Katja, Hugo, Sara, Reuter-Jessen, Kirsten, Körber, Wolfgang

2023

Overview

The identification of potential molecular alterations is standard in the diagnostic pathway of non-small-cell lung cancer (NSCLC). The aim of this study is to determine the prevalence of NTRK fusions in NSCLC in a routine diagnostic setting using immunohistochemistry, fluorescence in situ hybridization, and RNA-based next-generation sequencing. A total of 1068 unselected consecutive patients with NSCLC were screened in two scenarios, either with initial IHC followed by RNA-NGS (n = 973) or direct FISH testing (n = 95). In total, 0.2% of all patients were NTRK positive. Both RNA-NGS and FISH are suitable to determine clinically relevant NTRK fusions in a real-world setting. RNA-NGS or FISH NTRK positive results were mutually exclusive with alterations in EGFR/ALK/ROS1/BRAF/RET or KRAS. (1) Background: The main objectives of our study are (i) to determine the prevalence of NTRK (neurotrophic tyrosine kinase) fusions in a routine diagnostic setting in NSCLC (non-small cell lung cancer) and (ii) to investigate the feasibility of screening approaches including immunohistochemistry (IHC) as a first-line test accompanied by fluorescence in situ hybridization (FISH) and RNA-(ribonucleic acid-)based next-generation sequencing (RNA-NGS). (2) Methods: A total of 1068 unselected consecutive patients with NSCLC were screened in two scenarios, either with initial IHC followed by RNA-NGS (n = 973) or direct FISH testing (n = 95). (3) Results: One hundred and thirty-three patients (14.8%) were IHC positive; consecutive RNA-NGS testing revealed two patients (0.2%) with NTRK fusions (NTRK1-EPS15 (epidermal growth factor receptor pathway substrate 15) and NTRK1-SQSTM1 (sequestosome 1)). Positive RNA-NGS was confirmed by FISH, and NTRK-positive patients benefited from targeted treatment. All patients with direct FISH testing were negative. RNA-NGS- or FISH-positive results were mutually exclusive with alterations in EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), ROS1 (ROS proto-oncogene 1), BRAF (proto-oncogene B-Raf), RET (rearranged during transfection) or KRAS (kirsten rat sarcoma viral oncogene). Excluding patients with one of these alterations raised the prevalence of NTRK-fusion positivity among panTrk-(tropomyosin receptor kinase-) IHC positive samples to 30.5%. (4) Conclusions: NTRK fusion-positive lung cancers are exceedingly rare and account for less than 1% of patients in unselected all-comer populations. Both RNA-NGS and FISH are suitable to determine clinically relevant NTRK fusions in a real-world setting. We suggest including panTrk-IHC in a diagnostic workflow followed by RNA-NGS. Excluding patients with concurrent molecular alterations to EGFR/ALK/ROS1/BRAF/RET or KRAS might narrow the target population.

• Publisher: MDPI AG
• Subject: Cancer / Diagnosis / Genetic aspects / Immunohistochemistry / Lung cancer, Non-small cell / Lymphomas / Pharmaceutical industry / RNA / Tyrosine